Verona pharma submits new drug application to us fda for ensifentrine for the maintenance treatment of copd

London and raleigh, n.c., june 27, 2023 (globe newswire) -- verona pharma plc (nasdaq: vrna) (“verona pharma” or the “company”) announces the submission of a new drug application (“nda”) to the us food and drug administration (“fda”) for approval of ensifentrine for the maintenance treatment of patients with chronic obstructive pulmonary disease (“copd”).
VRNA Ratings Summary
VRNA Quant Ranking